MA54653B1 - Modulateurs du récepteur de cxcr7 pipéridine - Google Patents
Modulateurs du récepteur de cxcr7 pipéridineInfo
- Publication number
- MA54653B1 MA54653B1 MA54653A MA54653A MA54653B1 MA 54653 B1 MA54653 B1 MA 54653B1 MA 54653 A MA54653 A MA 54653A MA 54653 A MA54653 A MA 54653A MA 54653 B1 MA54653 B1 MA 54653B1
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- cxcr7
- receptor
- piperidine
- img
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention concerne des dérivés de pipéridine de formule (i) <img file="imga0001.Tif" frnum="0001" he="51" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="56"/> dans laquelle ar1, ar2, rar1, r1, r2 et r3 sont tels que décrits dans la description, leur préparation, leurs sels pharmaceutiquement acceptables, et leur utilisation comme produits pharmaceutiques, les compositions pharmaceutiques contenant un ou plusieurs composés de formule (i), et notamment leur utilisation comme modulateurs du récepteur cxcr7.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016068052 | 2016-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54653A MA54653A (fr) | 2021-12-29 |
| MA54653B1 true MA54653B1 (fr) | 2023-04-28 |
Family
ID=59656027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45782A MA45782B1 (fr) | 2016-07-28 | 2017-07-27 | Modulateurs du récepteur de cxcr7 pipéridine |
| MA54653A MA54653B1 (fr) | 2016-07-28 | 2017-07-27 | Modulateurs du récepteur de cxcr7 pipéridine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45782A MA45782B1 (fr) | 2016-07-28 | 2017-07-27 | Modulateurs du récepteur de cxcr7 pipéridine |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10752620B2 (fr) |
| EP (2) | EP3490986B1 (fr) |
| JP (2) | JP6655754B2 (fr) |
| KR (2) | KR102497095B1 (fr) |
| CN (2) | CN110563717B (fr) |
| AR (2) | AR109180A1 (fr) |
| AU (2) | AU2017302079B2 (fr) |
| BR (1) | BR112019001551A2 (fr) |
| CA (1) | CA3032017C (fr) |
| CL (2) | CL2019000169A1 (fr) |
| CY (1) | CY1125016T1 (fr) |
| DK (2) | DK3798217T3 (fr) |
| EA (2) | EA202091262A1 (fr) |
| ES (2) | ES2905755T3 (fr) |
| FI (1) | FI3798217T3 (fr) |
| HR (2) | HRP20230313T1 (fr) |
| HU (2) | HUE062019T2 (fr) |
| IL (2) | IL264424B (fr) |
| LT (2) | LT3490986T (fr) |
| MA (2) | MA45782B1 (fr) |
| MX (2) | MX2019001042A (fr) |
| MY (1) | MY198113A (fr) |
| NZ (1) | NZ751006A (fr) |
| PH (2) | PH12021552605A1 (fr) |
| PL (2) | PL3798217T3 (fr) |
| PT (2) | PT3798217T (fr) |
| RS (2) | RS62855B1 (fr) |
| SG (2) | SG10201906942PA (fr) |
| SI (2) | SI3798217T1 (fr) |
| TW (3) | TWI683812B (fr) |
| UA (1) | UA122987C2 (fr) |
| WO (1) | WO2018019929A1 (fr) |
| ZA (1) | ZA201901256B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2976567T3 (es) | 2018-01-26 | 2024-08-05 | Idorsia Pharmaceuticals Ltd | Formas cristalinas de (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico |
| PH12022551043A1 (en) | 2019-10-31 | 2023-05-03 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| CA3226468A1 (fr) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Derives de pyrazole microbiocides |
| KR102524669B1 (ko) * | 2021-10-01 | 2023-04-21 | 주식회사 넥스트젠바이오사이언스 | 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
| JP2024546927A (ja) | 2021-12-17 | 2024-12-26 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺微生物性ピラゾール誘導体 |
| EP4238970A1 (fr) * | 2022-03-03 | 2023-09-06 | InterAx Biotech AG | Modulateurs de ackr3 et leurs utilisations |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
| TW202434579A (zh) | 2022-11-16 | 2024-09-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物的四氫異喹啉衍生物 |
| WO2024115512A1 (fr) | 2022-11-30 | 2024-06-06 | Syngenta Crop Protection Ag | Dérivés de tétrahydroisoquinoline microbiocides |
| TW202439972A (zh) | 2022-11-30 | 2024-10-16 | 瑞士商先正達農作物保護股份公司 | 殺真菌組成物 |
| TW202435758A (zh) | 2023-01-27 | 2024-09-16 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202434112A (zh) | 2023-02-01 | 2024-09-01 | 瑞士商先正達農作物保護股份公司 | 殺真菌組成物 |
| WO2024256438A1 (fr) | 2023-06-14 | 2024-12-19 | Syngenta Crop Protection Ag | Compositions fongicides |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102324A1 (en) * | 2002-02-28 | 2004-05-27 | Annis Gary David | Heterocyclic diamide invertebrate pest control agents |
| JP4828829B2 (ja) | 2002-11-27 | 2011-11-30 | インサイト・コーポレイション | ケモカイン受容体のモジュレーターとしての３−アミノピロリジン誘導体 |
| TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2005032490A2 (fr) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Diamines cycliques et derives comme inhibiteurs du facteur xa |
| KR20070113233A (ko) * | 2005-02-18 | 2007-11-28 | 아스트라제네카 아베 | 항균성 피페리딘 유도체 |
| WO2010054006A1 (fr) * | 2008-11-04 | 2010-05-14 | Chemocentryx, Inc. | Modulateurs du cxcr7 |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
| WO2013084241A1 (fr) * | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Composés inhibiteurs de rénine |
| AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| EP2925745B1 (fr) * | 2012-11-29 | 2018-04-04 | ChemoCentryx, Inc. | Antagonistes de cxcr7 |
| UA118562C2 (uk) * | 2013-05-30 | 2019-02-11 | Ідорсія Фармасьютікалз Лтд | Модулятори рецептора cxcr7 |
| CA2923184A1 (fr) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Composes utiles comme immunomodulateurs |
| EP3041827B1 (fr) | 2013-09-06 | 2018-04-18 | Aurigene Discovery Technologies Limited | Dérivés 1,2,4-oxadiazole utilisés comme immunomodulateurs |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| SG11201701597RA (en) * | 2014-09-10 | 2017-03-30 | Epizyme Inc | Substituted piperidine compounds |
| EP3227263B1 (fr) | 2014-12-01 | 2019-04-10 | Idorsia Pharmaceuticals Ltd | Modulateurs du recepteur de cxcr7 |
| ES2976567T3 (es) | 2018-01-26 | 2024-08-05 | Idorsia Pharmaceuticals Ltd | Formas cristalinas de (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico |
-
2017
- 2017-07-27 DK DK20201796.8T patent/DK3798217T3/da active
- 2017-07-27 TW TW106125273A patent/TWI683812B/zh active
- 2017-07-27 CN CN201910748606.6A patent/CN110563717B/zh active Active
- 2017-07-27 CA CA3032017A patent/CA3032017C/fr active Active
- 2017-07-27 SI SI201731333T patent/SI3798217T1/sl unknown
- 2017-07-27 HU HUE20201796A patent/HUE062019T2/hu unknown
- 2017-07-27 KR KR1020207021496A patent/KR102497095B1/ko active IP Right Grant
- 2017-07-27 LT LTEPPCT/EP2017/068990T patent/LT3490986T/lt unknown
- 2017-07-27 NZ NZ751006A patent/NZ751006A/en unknown
- 2017-07-27 LT LTEP20201796.8T patent/LT3798217T/lt unknown
- 2017-07-27 DK DK17754283.4T patent/DK3490986T3/da active
- 2017-07-27 KR KR1020197005980A patent/KR102497091B1/ko active IP Right Grant
- 2017-07-27 UA UAA201901844A patent/UA122987C2/uk unknown
- 2017-07-27 TW TW108111236A patent/TWI691494B/zh active
- 2017-07-27 MY MYPI2019000420A patent/MY198113A/en unknown
- 2017-07-27 PT PT202017968T patent/PT3798217T/pt unknown
- 2017-07-27 ES ES17754283T patent/ES2905755T3/es active Active
- 2017-07-27 WO PCT/EP2017/068990 patent/WO2018019929A1/fr active Application Filing
- 2017-07-27 AU AU2017302079A patent/AU2017302079B2/en active Active
- 2017-07-27 HR HRP20230313TT patent/HRP20230313T1/hr unknown
- 2017-07-27 TW TW108111240A patent/TWI691497B/zh active
- 2017-07-27 PH PH1/2021/552605A patent/PH12021552605A1/en unknown
- 2017-07-27 SG SG10201906942PA patent/SG10201906942PA/en unknown
- 2017-07-27 MA MA45782A patent/MA45782B1/fr unknown
- 2017-07-27 JP JP2019503918A patent/JP6655754B2/ja active Active
- 2017-07-27 EP EP17754283.4A patent/EP3490986B1/fr active Active
- 2017-07-27 EP EP20201796.8A patent/EP3798217B1/fr active Active
- 2017-07-27 HU HUE17754283A patent/HUE057315T2/hu unknown
- 2017-07-27 SI SI201731053T patent/SI3490986T1/sl unknown
- 2017-07-27 EA EA202091262A patent/EA202091262A1/ru unknown
- 2017-07-27 AR ARP170102126A patent/AR109180A1/es unknown
- 2017-07-27 SG SG11201900633XA patent/SG11201900633XA/en unknown
- 2017-07-27 PT PT177542834T patent/PT3490986T/pt unknown
- 2017-07-27 RS RS20220082A patent/RS62855B1/sr unknown
- 2017-07-27 EA EA201990388A patent/EA037507B1/ru not_active IP Right Cessation
- 2017-07-27 PL PL20201796.8T patent/PL3798217T3/pl unknown
- 2017-07-27 CN CN201780046279.9A patent/CN109563085B/zh active Active
- 2017-07-27 MA MA54653A patent/MA54653B1/fr unknown
- 2017-07-27 RS RS20230297A patent/RS64130B1/sr unknown
- 2017-07-27 ES ES20201796T patent/ES2954152T3/es active Active
- 2017-07-27 US US16/320,906 patent/US10752620B2/en active Active
- 2017-07-27 PL PL17754283T patent/PL3490986T3/pl unknown
- 2017-07-27 MX MX2019001042A patent/MX2019001042A/es unknown
- 2017-07-27 BR BR112019001551-5A patent/BR112019001551A2/pt active Search and Examination
- 2017-07-27 HR HRP20211988TT patent/HRP20211988T1/hr unknown
- 2017-07-27 FI FIEP20201796.8T patent/FI3798217T3/fi active
-
2019
- 2019-01-22 CL CL2019000169A patent/CL2019000169A1/es unknown
- 2019-01-23 IL IL264424A patent/IL264424B/en unknown
- 2019-01-24 MX MX2021004000A patent/MX2021004000A/es unknown
- 2019-01-25 PH PH12019500188A patent/PH12019500188A1/en unknown
- 2019-02-27 ZA ZA2019/01256A patent/ZA201901256B/en unknown
- 2019-03-15 JP JP2019048980A patent/JP6655742B2/ja active Active
- 2019-07-01 AR ARP190101842A patent/AR115662A2/es unknown
- 2019-11-15 CL CL2019003281A patent/CL2019003281A1/es unknown
-
2020
- 2020-07-09 AU AU2020204578A patent/AU2020204578B2/en active Active
- 2020-07-14 US US16/928,787 patent/US11306078B2/en active Active
-
2021
- 2021-05-05 IL IL282942A patent/IL282942B/en unknown
-
2022
- 2022-02-21 CY CY20221100143T patent/CY1125016T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA31754B1 (fr) | Cis-imidazolines chirales | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA46038B1 (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA32764B1 (fr) | Inhibiteurs de l'intégrase du vih | |
| MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique |